Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded up 42.9% on Tuesday . The company traded as high as C$0.11 and last traded at C$0.10. 340,639 shares changed hands during trading, an increase of 259% from the average session volume of 94,981 shares. The stock had previously closed at C$0.07.
Hemostemix Trading Up 57.1 %
The company has a market capitalization of C$9.58 million, a PE ratio of -5.50 and a beta of 0.20. The firm has a 50 day simple moving average of C$0.08 and a two-hundred day simple moving average of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Why Are Stock Sectors Important to Successful Investing?
- 3 Stocks Helping to Bring AI to Healthcare
- How to Invest in Biotech Stocks
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- What Are Dividend Champions? How to Invest in the Champions
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
